Shares are Biogen spiked on the aducanumab data leak as investors with unfair access to what was supposed to be embargoed results traded on the information.
Voyager's gene therapy aims to turn back the clock so advanced Parkinson's patients respond better and longer to the standard drug used to treat the brain disease.
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
I spent the weekend with thousands of blood disease researchers. This is what happened.